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Micro-electrode arrays (MEAs) are increasingly used to characterize neuronal network activity of human induced pluripotent stem
cell (hiPSC)-derived neurons. Despite their gain in popularity, MEA recordings from hiPSC-derived neuronal networks are not al-
ways used to their full potential in respect to experimental design, execution, and data analysis. Therefore, we benchmarked the
robustness of MEA-derived neuronal activity patterns from ten healthy individual control lines, and uncover comparable network
phenotypes. To achieve standardization, we provide recommendations on experimental design and analysis. With such standard-
ization, MEAs can be used as a reliable platform to distinguish (disease-specific) network phenotypes. In conclusion, we show
that MEAs are a powerful and robust tool to uncover functional neuronal network phenotypes from hiPSC-derived neuronal net-
works, and provide an important resource to advance the hiPSC field toward the use of MEAs for disease phenotyping and drug
discovery.
INTRODUCTION
In vitro neuronal models have become an important tool
to study the complex communication of healthy and
diseased neuronal circuits. In particular, the possibility
to measure and manipulate the electrical activity ex-
hibited by neuronal populations gives insight into
neuronal network development and organization (Ka-
mioka et al., 1996; Maeda et al., 2016; Novellino et al.,
2011). Micro-electrode arrays (MEAs) are cell culture
dishes with embedded micro-electrodes that allow non-
invasive measurement of neuronal network activity.
MEAs have been extensively used to measure activity
from a range of different neuronal culture systems, for
example, primary cell cultures, brain slices, or intact ret-
inas, mainly from rodent origin (McConnell et al.,
2012). With the advancements in human induced plurip-
otent stem cell (hiPSC) technology, the differentiation of
human neurons from somatic cells became possible, al-
lowing phenotyping of human neuronal networks.
hiPSC-derived neuronal networks on MEA mimic the ac-
tivity pattern of rodent neuronal networks, including a
stable state of synchronized network bursting, suggesting
that they successfully develop into functional neuronal
networks (Frega et al., 2019; Fukushima et al., 2016;
Kayama et al., 2018; Odawara et al, 2014, 2016; Sasaki
et al., 2019). In addition, improvements in MEA analysis
software simplified the extraction of parameters that
describe the pattern of neuronal activity. These advance-
ments in both human neuronal culturing systems and
MEA analysis software contributed to the popularity of
MEA technology to study neuronal network phenotypes
(Deneault et al., 2019; Frega et al., 2019; Klein Gunnewiek
et al., 2020; Wainger et al., 2014).
Despite its increasing popularity, MEA technology is not
always used to its full potential to investigate hiPSC-
derived neuronal network characteristics. hiPSC-derived
neuronal networks have not been benchmarked as exten-
sively as rodent neuronal cultures. Because of the lack of
standardization, it remains undetermined how changes
in cell culture conditions influence batch-to-batch consis-
tency, and whether hiPSC-derived neuronal networks
from different lines are comparable (Engle et al., 2018).
It is advised to use multiple hiPSC-derived neuronal lines
or isogenic sets to reliably determine a disease phenotype,
since differences in genetic background between hiPSC
donors dominate the variance at the transcriptional level
(Germain and Testa, 2017). However, little is known about
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the amount of cell lines needed to distinguish a pheno-
type on MEAs, or about the effect of genetic background
on hiPSC-derived neuronal network function. In addition
to experimental design, data analysis remains a hurdle,
even though the extraction of MEA parameters became
easier. Studies often quantify the general neuronal
network activity by a single parameter (i.e., mean firing
rate), thereby failing to explain the complex network
characteristics. Finally, cell culture practices are not always
optimized and thus mature networks, showing network
synchronicity, are not always obtained. In summary, the
question remains how reproducible and comparable
MEA recordings are within and between different lines,
different researchers, and across different batches or devel-
opmental time points, illustrating the need for a quality
standard.
Here, we provide a set of recommendations for the
design, analysis, and interpretation of hiPSC-derived
neuronal networks on MEAs. We performed a meta-anal-
ysis of MEA recordings from excitatory neuronal networks
generated through one of the most widely used differenti-
ation protocols (i.e., Ngn2 induction [Frega et al., 2017;
Zhang et al., 2013]). Specifically, we used hiPSCs derived
from ten healthy subjects (controls), which were cultured
by different researchers over a period of several years. We
show that different control neuronal networks cultured
on MEAs are highly comparable, and identify the most
robustMEA parameters to describe neuronal network activ-
ity and organization. When pooling data from all control
lines, the functional activity of control neuronal networks
is not largely influenced by biological differences between
donors (i.e., age, sex). Finally, using neuronal networks
affected by genetic aberrations causing Kleefstra syndrome
(KS) or mitochondrial encephalopathy, lactic acidosis, and
stroke-like episodes (MELAS), we show that the MEA plat-
form is a powerful tool to identify genotype-phenotype
correlations.
RESULTS
Excitatory neurons derived from healthy subjects
show a comparable phenotype on MEA
To investigate if neuronal network activity from hiPSC-
derived Ngn2-induced excitatory neurons was reproduc-
ible, we performed a meta-analysis on MEA data derived
from multiple control lines used in our lab (Frega et al.,
2019; Klein Gunnewiek et al., 2020; Mossink et al., 2021).
The control lines were derived from fibroblast skin biopsies
from ten healthy individuals, five males and five females,
with a mean age of 33.5 years (Figure 1A), and we extracted
17 parameters in total to describe the neuronal network ac-
tivity and connectivity (Table S1).
During the first 2 weeks of differentiation, neuronal
network activity primarily consisted of random spikes (iso-
lated asynchronous spikes) and bursts (high frequency ac-
tion potentials), which, during development, organized
into network bursts (rhythmic, synchronous events) (Fig-
ures 1B and 1C). During maturation, Ngn2-induced
neuronal networks displayed an increase in firing rate
(MFR) and (network) bursting rate ([N]BR), and a decrease
in (network) burst duration ([N]BD), and percentage of
random spikes (PRS) (Figures 1D–1G and S1A–S1E). From
27 days in vitro (DIV) onward, these parameters plateaued,
and neuronal network activity remained stable (blue
boxes). Because these neuronal networks were generally
measured in this stable period (DIV 27–35), we pooled
data in this developmental window. In this specific time
window, we observed similar patterns of activity and con-
nectivity across all control lines (Figures 1H, S1F–S1O, S2,
and S3).
We next determined the specific range of values for each
parameter that described the neuronal network phenotype
(Figures 1I and S3F; Table S2). Control neuronal networks
showed a general level of activity of 3.5 ± 0.2 spike/s, 4.8 ±
0.2 bursts/min, and 3.2 ± 0.1 network bursts/min, with a
Figure 1. Control neuronal networks show a stable phenotype on MEA
(A) Information regarding the ten control lines used in this study. C6 was recorded on two substrates (H, human laminin; M, mouse
laminin). Number of wells represents total number of wells recorded for that line between DIV 27 and 35, including the number of batches.
Some batches overlap between lines.
(B) Schematic overview of extracted parameters from MEA (see Table S1).
(C) Representative raster plots of line C6 showing 60 s of electrophysiological activity across development (DIV 14–42).
(D–G) Neuronal network parameters (of line C6) develop to reach a certain plateau after DIV 27 (blue box) for (D) MFR, (E) PRS, (F) NBR, and
(G) NBD.
(H) Representative raster plots of ten control lines showing 3 min of electrophysiological activity on MEAs.
(I) Graph showing the range in which MEA parameters of all ten control lines behave (mean ±95% confidence interval). Values are first
averaged per control line, and then averaged across all control lines.
(J) Percent coefficient of variation explaining the stability of the respective MEA parameter across all ten control lines (mean ± standard
deviation of the mean). N = 278 wells (Table S2).
DIV, days in vitro; MFR, mean firing rate; PRS, percentage of random spikes; BR, mean burst rate; BD, mean burst duration; BSR, burst spike
rate; IBI, inter-burst interval; NBR, network burst rate; NBD, network burst duration; NIBI, network burst IBI; CVNIBI, coefficient of
variation of all NIBI’s representing the regularity of the NB; RT, rise time; DT, decay time. All means are reported in Table S2.
2184 Stem Cell Reports j Vol. 16 j 2182–2196 j September 14, 2021
(legend on next page)
Stem Cell Reports j Vol. 16 j 2182–2196 j September 14, 2021 2185
duration of 1.28± 0.04 s (nwells = 278).We did observe slight
differences between individual control lines. For example,
control lines C2 and C9 exhibited synchronous events at
different frequencies compared with the other controls
(i.e., 1.4 ± 0.2 and 4.6 ± 0.3 network bursts/min for C2 and
C9, respectively, Figure S1M), stressing the need of using
multiple lines to uncover the full phenotypic spectrum of
control neuronal networks. Taken together, these results
indicate that neuronal networks on MEA show similar pat-
terns of activity across multiple control lines.
Next, we investigated the variability of the MEA parame-
ters within our control dataset to identify the most robust
parameters (i.e., coefficient of variation lower than 50%
as cutoff, Figures 1J and S3G). Certain parameters were
more stable (i.e., frequency and duration of NBR and
NBD, respectively), whereas others were more variable,
i.e., MFR, the regularity of the network burst appearance,
calculated as the coefficient of variation of the interval dis-
tribution between network bursts (CVNIBI), the degree of
synchronization (C0), and link weight. In most of the
hiPSC-based MEA studies, the MFR has been used as the
main and only parameter, which may confound the char-
acterization and interpretation of the neuronal network
behavior. Beside the fact that MFR is one of the most vari-
able parameters reported here, it is highly dependent on
cell density (Biffi et al., 2013) and lacks information about
network synchronization. Multiple MEA parameters
describing both general activity and bursting behavior
should be included to obtain a comprehensive character-
ization of neuronal network behavior.
Confounding factors in experimental design,
culturing, and analysis that influence the reliability of
neuronal network recordings
Combining all MEA parameters in a principal-component
analysis (PCA), we did not observe clear clustering based
on hiPSC line (Figure 2A), indicating that there was no
consistent line-specific difference at the functional level.
To guarantee these reliable neuronal network recordings,
we explored which confounding factors introduce varia-
tion. Sex and age of the original fibroblast donor had no
major effect on the neuronal network phenotype vari-
ability (Figures 2B and 2C). Furthermore, we found no clear
clustering based on DIV when the cultures reached a stable
developmental stage (i.e., DIV 27–35, Figure 2D). However,
neuronal networks measured earlier (DIV 14–24) clustered
away from measurements performed after DIV 28 (Fig-
ure S1P). Thus, pooling data from different developmental
stages should be avoided since it likely introduces variation
in the data.
Next, we explored whether culturing conditions intro-
duced variation. First, we observed no clear difference be-
tween neuronal networks grown on two types of coating
(mouse or human laminin) at the stable developmental
stage (Figure 2E). However, different developmental trajec-
tories have been observed in neuronal networks grown on
mouse and human laminin (Hyysalo et al., 2017), thus
pooling and comparison of data from different coatings
can affect their comparability. Another culturing variable
that could influence network activity is cell distribution.
With low-resolution MEA systems (i.e., 12 electrodes
Figure 2. Variables that influence neuronal network phenotype
(A–E) Principal-component analysis (PCA) plot on all parameters showing data of all control lines pooled from DIV 27 to 35 (A) color coded
by line, (B) color coded by sex, (C) color coded by the fibroblast age at biopsy, (D) color coded by DIV, and (E) color coded by laminin
origin.
(F) Representative images of neuronal cultures grown at different densities and distributions (even, uneven, and low densities, and
extreme clustering) and representative raster plots showing 1 min of activity exhibited by neuronal networks in each condition.
(G) Representative raster plots of a well in which the network burst detection was adapted to detect all network burst present. Colored bars
represent the detected network burst by software. Comparison of the MEA parameters NBR, NIBI (on log2 scale), and CVNIBI between
control pool (Call gray), wells in which not all network burst have been detected (Csuboptimal, red), and the same wells when optimal
detection have been performed (Coptimal, green) (mean ± standard error of the mean). Kruskal-Wallis ANOVA with Dunn’s correction for
multiple testing was used to compare between control lines.
(H) Representative raster plots of C1 and a well in which only a few channels are active. In the figure, the electrodes used for analysis are
highlighted (green and red for three active electrodes and all electrodes, respectively). Comparison of the MEA parameters MFR and NBR
between C1, a well in which the analysis has been performed only on active electrode (Cactive el, red) and the same well when the analysis
has been performed on all electrodes (Call el, green) (mean ± standard error of the mean). One-way ANOVA with Tukey correction for
multiple testing was used to compare between control lines.
(I) PCA plot on all parameters showing data of one control line (C1) with colors representing MEA batches and shapes representing
astrocyte batches.
(J) Percentage of variance explained by astrocyte batch and MEA batch, calculated based on separate linear models to determine the
effects of astrocyte and MEA batch independently.
*p = 0.05, **p = 0.01, ***p = 0.001. DIV, days in vitro; MFR, mean firing rate; PRS, percentage of random spikes; NBR, network burst rate;
NBD, network burst duration; NIBI, network burst IBI; CVNIBI, coefficient of variation of all NIBI’s representing the regularity of the NB. All
means, p values, and statistic tests used are reported in Table S4.
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spaced 300 mm apart), the activity recorded from the elec-
trodes originates frommultiple neurons. Therefore, homo-
geneous distribution of cells on each electrode should be
achieved. Indeed, we found that changes in cell density
and distribution affected neuronal network functionality
(Figure 2F). While an even distribution of neurons on all
electrodes was accompanied by synchronous activity
involving all channels, an uneven distribution led to
events involving only a few channels (Figure 2F, second
panel). In addition, neuronal networks with (extreme)
low densities exhibited less frequent events (Figure 2F,
third panel) or only random spikes (Figure 2F, third panel).
Cell clustering led to highly frequent local activity, re-
corded only by the electrodes close to the cluster (Figure 2F,
fourth panel). Thus, cell density and distribution should be
consistent to achieve a comparable network pattern, and a
density that allows for proper neuron-electrode coupling
should be chosen (1,200 cells/mm2 in this dataset).
Neuronal networks with low cell density, clustering, or un-
even distribution of cells should be excluded from the
analysis.
In addition to culturing conditions, accurate data anal-
ysis depended on the selection of proper analysis settings.
Suboptimal network burst detection (i.e., not all network
bursts were correctly detected) (Figure 2G) sometimes
occurred by adhering to the standard settings of the anal-
ysis software, or too stringent settings determined by the
experimenter. Visually, raster plots of suboptimal detected
control networks did not differ from raster plots of the total
control pool. However, comparing suboptimal detected
control networks with the total control pool resulted in a
faulty quantification of the neuronal network organization
(Figure 2G, Csuboptimal versus Call). When the analysis set-
tings of suboptimal detected networks were changed to
more optimal detection settings (i.e., the settings that
correctly quantify each network burst, determined by the
experimenter’s observation for each individual recording),
no difference between the two groups was present (Coptimal
versus Call), as expected from the raster plot. Thus, the ex-
perimenter’s observation and intervention on data analysis
for each recording is essential to obtain accurate results.
Similarly, data analysis performed on individual active elec-
trodes led to erroneous results when culturing conditions
were not optimal (Figure 2F). When we analyzed only the
active electrodes in wells with uneven densities, we ob-
tained similar activity patterns as in wells with an optimal
density in which all electrodes were analyzed, resulting in
an incorrect representation of the actual neuronal network
(Figure 2H, Cactive el. versus C1). Analysis on all electrodes,
however, provided a correct image of the neuronal network
phenotype (Call el. versus C1). Thus, stringent criteria
should be used when performing data analysis. Control
neuronal networks should display at least certain activity
levels to be included in further analysis, including an
MFR > 0.1 spike/s, a BR > 0.4 bursts/min, and an NBR > 1
network burst/min, and synchronous activity should be
observed in most of the channels. General activity (i.e.,
spikes) should be detected in at least 80% of the electrodes
and analysis should be performed on all electrodes rather
than only on the active ones.
Finally, we investigated the effect of both independent
astrocyte batches and MEA batches (i.e., independent
neuronal preparations on MEA) on the neuronal network
behavior. PCA showed that samples cluster based on astro-
cyte and MEA batch (Figure 2I), indicating that different
batches affected the neuronal network phenotype. We
calculated the percentage of variance explained by astro-
cyte batch and MEA batch separately. On all MEA parame-
ters combined, astrocyte batch explained 32% of the varia-
tion and MEA batch explained 69% of the variation
(Figure 2J). The PRS, burst spike rate (BSR), BD, NBD, and
decay time (DT) were significantly affected by both astro-
cyte batch andMEA batch (adj. p < 0.05) (Table S4). In addi-
tion, MEA batch significantly affected the BR, NBR,
network inter-burst interval (NIBI), and rise time (RT)
(adj. p < 0.05) (Table S4). These results stress the need for us-
ing multiple experimental batches when comparing
different lines to correct for this technical variation (i.e.,
at least two MEA batches, preferentially with astrocytes
belonging to the same batch).
In summary, our results indicate that certain standards
should be followed to ensure that reliable data were ob-
tained fromMEA experiments (Table 1). To generate repro-
ducible neuronal control network phenotypes, one needs
to (1) culture sufficient neurons that are homogeneously
distributed, (2) properly select the detection settings, (3)
pool data only in a certain developmental time window,
and (4) use sufficient experimental batches.
The MEA system is a reliable platform for disease
phenotyping
To confirm that control neuronal networks can be used as a
platform for disease phenotyping, we compared patient
neuronal network activity from two neurodevelopmental
disorders (NDD) with the total control pool. In particular,
we re-analyzed our previously published data from three
patients with MELAS syndrome (two females and one
male, mean age 34.7 years) (Klein Gunnewiek et al.,
2020) and four patients with KS (three females and one
male, mean age 27.5 years) (Frega et al., 2019) (Figure 3A).
Since control neuronal networks were stable between DIV
27 and 35, recordings from MELAS patient lines (nwells =
112), as well as KS patient lines (nwells = 58), were pooled
in the same time window.
Neuronal networks from MELAS patients showed a
different network phenotype compared with the control
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pool (Figure 3B). In line with previous findings (Klein Gun-
newiek et al., 2020), the phenotype was mainly driven by a
strong reduction in level of spiking and network bursting
activity, together with an increased PRS (Figures 3C–3F).
In addition to previously published data, MELAS neuronal
networks exhibited bursts with a shorter duration
compared with the control pool (Figure 3E). We did not
observe any difference in burst shape, RT, or DT of MELAS
patient network bursts (Figure S4A). Neuronal networks
derived fromMELAS patients did show a lower level of cor-
relation (Cpeak) and synchronization (C0) in all channels
(Figure S4B). Furthermore, despite a comparable number
of functional connections among electrodes in control
and MELAS patient neuronal networks, we observed that
the connections between MELAS neurons were weaker
(Figure S4C). PCA confirmed that MELAS patient networks
clustered separately from controls (Figure 3L).
Next, we compared neuronal networks from patients
with KS with our total control pool and uncovered a signif-
icantly different network phenotype (Figure 3B). In line
with previously published findings (Frega et al., 2019),
the KS phenotype was mainly characterized by a lower fre-
quency of (network) bursts with a longer duration (Figures
3G–3I). In addition, KS neuronal networks exhibited a
different network burst shape and an increased DT (Figures
3J and 3K), and showed a lower level of synchronicity and
correlation and weaker connections between neurons
compared with controls (Figures S4D and S4E). We
observed that the differences between patients and con-
trols were more pronounced in KS4 as compared with the
other KS lines (Figure S4F). PCA confirmed that KS
neuronal networks clustered away from controls based on
these parameters (Figure 3M).
In conclusion, the neuronal network phenotypes of
MELAS and KS lines differed from controls on distinct pa-
rameters. Indeed, MELAS and KS samples cluster away
from controls, but also clearly cluster away from each other
(Figure 3N). The ability to distinguish two NDDs based on
their neuronal network phenotypes demonstrates that the
MEA system is an adequate platform for disease-specific
phenotyping.
Comparing patients with isogenic controls reveals a
more detailed phenotype
IsogenichiPSC lines are increasingly used to improve identi-
fication of genotype-phenotype correlations. We compared
data from threeMELASmosaic patient-control isogenic sets,
one KSmosaic patient-control set and one KS CRISPR-Cas9-
engineered isogenic set. The difference between each
MELAS and KS isogenic set was explained by the same pa-
rameters as when patient lines were compared with all con-
trol lines (Figures 3 and4).We also found that the difference
betweenpatient and control lineswas larger for isogenic sets
compared with all lines combined, as indicated by the
higher variance explained by disease status (Figures 3L,
3M, 4G, and 4N).
Table 1. List of recommendations
Experimental design 12 wells per condition, divided over 2 MEA
batches
page 9, paragraph 1
comparison of at least 3 control or patient
lines
page 9
inclusion of isogenic patient-control set page 7
Cell culturing homogeneous distribution of cells page 6, paragraph 1 Figure 2F
cell density allowing neuron-electrode
coupling (i.e., 1,200 cells/mm2)
page 6, paragraph 1
same astrocyte batch for conditions under
comparison
page 6, paragraph 2
Data analysis analyze multiple MEA parameters page 6, 7, 9
pooling of data only in similar developmental
stages
page 5, paragraph 2 Figure S1H
in control: MFR > 0.1 spike/s, BR > 0.4 bursts/
min, NBR > 1 NB/min, active channels > 80%,
channels in NB > 25%
page 6
analysis on all electrodes page 6, paragraph 1 Figure 2H
Recommendations are provided regarding experimental design, cell culture conditions, and MEA data analysis. Page numbers, including paragraph numbers
are shown, which refer to sections of the text that provide information and data to support our recommendations.
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For some parameters, we observed smaller differences in
one MELAS set (i.e., isogenic set 1) as compared with the
other isogenic sets (Figures 4A–4E). This was mainly driven
by a difference in the isogenic control (C2) compared with
all controls, rather than a less pronounced MELAS pheno-
type (Figures S1F–S1O). While comparing isogenic sets,
we found a significant difference in the network burst
shape of two MELAS isogenic patient-control sets (Fig-
ure 4F), a phenotype that was not distinguished when
comparing MELAS patients to control pool. Some line-spe-
cific differences were also found in theMEA parameters, ex-
plaining the KS network phenotype. Whereas the DT was
not affected in KS3 compared with its isogenic control,
and only a trend was observed in network burst duration
for KS4, these parameters were altered in all other KS lines
(Figures 4K–4M, and S4G). Post hoc power calculation re-
vealed that the parameters that explained the MELAS and
KS phenotypes reached a power higher than 0.95 (Table
S3), demonstrating the validity of our results. When per-
forming an a priori power calculation on each patient-con-
trol isogenic set or all controls compared with all patient
lines, we found that a minimum of 12 wells per line should
be included in the analysis to observe a patient phenotype
on multiple MEA parameters (Table S3).
To conclude, disease phenotypes are generally consistent
between different lines from patients with the same disor-
der, even though some line-specific differences can be
observed. This persisted when MELAS and KS lines were
compared with their corresponding isogenic controls,
highlighting the importance of usingmultiple patient lines
to uncover the full phenotypic spectrum. Nevertheless, we
show that isogenic patient-control sets uncover more pro-
nounced phenotypes, emphasizing the advantage of
isogenic sets.
DISCUSSION
Despite the increasing popularity of MEAs for disease phe-
notyping of hiPSC-derived neuronal networks, there is lit-
tle insight into the variability of control networks and
which conditions influence this. Here, we performed a
meta-analysis of, to our knowledge, the largest dataset of
hiPSC-derivedNgn2-induced excitatory neuronal networks
on MEA, to describe a standard for control network signa-
tures. We uncovered that neuronal networks derived from
ten different healthy subjects clustered together in PCA,
regardless of whether they were cultured by different re-
searchers over the course of years, and independent of
sex and age at fibroblast biopsy.
These control neuronal networks were very comparable
because we adhered to a strict set of guidelines (Table 1).
First, networks could only be pooled in the time window
between DIV 27 and 35, as networks generated by Ngn2
overexpression in our lab presented stable activity at this
stage. Many factors can influence the timing of this stable
network activity. For example, Ngn2-neurons mature
significantly faster than neurons generated using small-
molecule supplementation protocols (Mertens et al.,
2016). In addition, while neuronal networks grown on hu-
man or mouse laminin showed no difference after DIV 28,
cultures grown on human laminin can mature slower (Hy-
ysalo et al., 2017). Therefore, one must define the stable
developmental period depending on each protocol, before
pooling and comparing data.
Second, as hiPSC culture practices and differentiation
protocols consist of many steps, small differences in
handling cells can accumulate over time into different out-
comes (Volpato and Webber, 2020). We showed that astro-
cyte and MEA batch introduced variability, and advise to
Figure 3. MEAs pose a reliable platform for genotype-phenotype correlations
(A) Information regarding the seven patient lines included in this study. Isogenic controls represent the lines made from the same founder
somatic cell line. Number of wells represents total number of wells recorded for that line between DIV 27 and 35, including the number of
batches. Some batches overlap between lines.
(B) Representative raster plots showing 3 min of electrophysiological activity from control, MELAS, and KS patient lines.
(C–F) Graphs showing the values of four MEA parameters, including (C) PRS, (D) MFR, (E) BD, and (F) NBR for control and MELAS neuronal
networks (mean ± standard error of the mean).
(G–J) Graphs showing four MEAs, including (G) BD, (H) NBR, (I) NBD, and (J) DT for control and KS neuronal networks (mean ± standard
error of the mean). Mann-Whitney U test with Bonferroni correction for multiple testing was used to compare between patient lines and
their isogenic controls (Table S4).
(K) Representative network burst alignment from one recording of a representative control and KS1, and a representative control and KS2.
Inset: extracted burst shape and representative raw trace of a network burst (sample size for C representative: C6, n = 58, C9, n = 12, KS1, n =
15, KS2, n = 15, multiple t test on bins using the Holm-Sidak method, p < 0.0001 for both comparisons).
(L) PCA plot on 7 MEA parameters, showing parameters that explain the differences in network behavior between Call (278 wells from 10
control lines) and M1-3.
(M) PCA plot on 12 MEA parameters, showing parameters that explain the differences in network behavior between Call and KS1-4.
(N) 3D scatterplot showing PRS, BD, and NBR for all MELAS (green), KS (red), and control lines (gray).
**p = 0.01 and ***p = 0.001. DIV, days in vitro; MFR, mean firing rate; PRS, percentage of random spikes; BD, mean burst duration; NBR,
network burst rate; NBD, network burst duration; DT, decay time. All means, p values, and statistic tests used are reported in Table S4.
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use at least twoMEA batches with the same astrocyte batch.
As an exception, one MEA batch can be used in drug-
screening assays, when cell line variability is accounted
for by comparing interventions. In addition, we advise to
exclude wells with low or uneven cell density and critically
look at the density and distribution on the electrode grid in
conjunction with the corresponding data.
Third, it is essential to accurately analyze the data and
include multiple parameters that describe the network ac-
tivity. The choice of the analysis settings for data extraction
can largely influence the results. Indeed, we showed that
these settings need to be fine-tuned, depending on the
observation of the experimenter to accurately detect
different phenotypic signatures. Network bursts exhibited
by patient-derived neuronal networks might be incorrectly
detected with commonly used settings, since these were
conventionally chosen based on network bursts in control
networks. Moreover, it is possible that the observed pheno-
type cannot be described using any of the commonly used
parameters, and new parameters should be introduced to
capture these signatures. Indeed, we showed that the
extraction of additional parameters from MEA data re-
vealed previously unseen phenotypes.
Finally, we determined the MEA parameter variability,
since stable parameters are themost trustworthy to identify
a disease phenotype. Interestingly, our data show that the
MFR is one of the most variable parameters. In addition,
it only describes the general level of activity and is largely
dependent on cell density. TheMFR should therefore be in-
terpreted with caution when solely used to describe a
phenotype, while this is a common practice in the litera-
ture, as it is easily extracted from the data (Chailangkarn
et al., 2017; Lu et al., 2016;Wainger et al., 2014). Other var-
iable parameters that we determined here (IBI, CVNIBI, RT,
C0, and link weight), can also be linked to alterations in
cell density. To use MEA parameters with high variability
to determine a patient phenotype, one should includemul-
tiple supporting MEA parameters to describe the neuronal
network characteristics.
We found a strong segregation between control and
MELAS and KS neuronal networks. More interestingly, we
found that KS and MELAS neuronal networks were distin-
guished by different MEA parameters, indicating the po-
tential of MEA recordings to distinguish two different
NDD phenotypes. Previous literature showed that
neuronal networks with different mutations associated
with the same NDD depicted a similar phenotype, albeit
characterized by an individual set of parameters. For
example, we previously identified that rat cortical networks
deficient for the KS spectrum genes Ehmt1,Mll3,Mbd5, and
Smarcb1 all displayed hyperactive neuronal networks.
However, whereas EHMT1- and SMARCB1-deficient net-
works showed a significantly higher MFR, MLL3-deficient
networks showed a higher NBR (Frega et al., 2020). Like-
wise, a recent study that investigated Ngn2-induced
neuronal network behavior of 12 autism spectrum disorder
patients revealed hyperactive neuronal networks specif-
ically from a patient with CNTN5 and a CRISPR-Cas9-engi-
neered line with an EHMT2 mutation (Deneault et al.,
2019). Together, this strengthens the evidence that early
disease-associated network phenotypes can be revealed us-
ing MEAs, and that hiPSC-derived neurons are a powerful
model to study genotype-phenotype correlations.
Although the phenotype of control neuronal networks
was robust, it must be noted that we still observed
significant variation between individual control lines, and
a similar variation was observed in the patient
neuronal network phenotype. While we cannot rule out a
Figure 4. Characterization of isogenic control and patient networks
(A) Representative raster plots showing 1 min of activity from three control (C2, C4, C5)-MELAS (M1-3) isogenic sets.
(B–E) Comparison of the MEA parameters (B) MFR, (C) PRS, (D) BD, and (E) NBR for each corresponding MELAS isogenic patient-control set
(mean ± standard error of the mean).
(F) Burst shape and representative raw trace of a network burst from C2 and M1, C4 and M2, and C5 and M3 (sample size for C2, n = 15, C4,
n = 23, C5, n = 55, M1, n = 22, M2, n = 8, and M3, n = 7, multiple t test on bins using the Holm-Sidak method, C2 versus M1, p < 0.001; C5 versus
M3, p = 0.00021) (Table S4).
(G) PCA plots on seven7 MEA parameters for MELAS isogenic patient-control sets C2 and M1, C4 and M2, and C5 and M3 showing MEA
parameters affected in MELAS.
(H) Representative raster plots showing 1 min of activity from two control (C9-10)-KS patient (KS3-4) isogenic sets.
(I–L) Comparison of the MEA parameters (I) BD, (J) NBR, (K) NBD, and (L) DT for each corresponding KS isogenic patient-control set
(mean ± standard error of the mean).
(M) Burst shape and representative raw trace of a network burst from C9 and KS1, C10 and KS4 (sample size for C9, n = 12, C10, n = 17, KS3,
n = 16, and KS4, n = 12, multiple t test on bins using the Holm-Sidak method) (Table S4).
(N) PCA plot on 12 MEA parameters for KS isogenic patient-control sets C9 and KS3 and C10 and KS4 showing MEA parameters affected in KS.
*p = 0.05, **p = 0.01, ***p = 0.001. DIV, days in vitro; MFR, mean firing rate; PRS, percentage of random spikes; BR, mean burst rate; BD,
mean burst duration; BSR, burst spike rate; IBI, inter-burst interval; NBR, network burst rate; NBD, network burst duration; NIBI, network
burst IBI; CVNIBI, coefficient of variation of all NIBI’s representing the regularity of the NB; RT, rise time; DT, decay time. All means,
p values, and statistic tests used are reported in Table S4.
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patient-specific component, this variation likely reflects
normal variation in the general population (Germain and
Testa, 2017). Gene expression and DNA methylation pro-
files vary significantly among hiPSC lines, of which com-
mon genetic variation is the main driver (DeBoever et al.,
2017; Germain and Testa, 2017; Kilpinen et al., 2017).
Indeed, previous literature uncovered that the heterogene-
ity within 25 different hiPSC lines on a transcriptional level
was due to differences in genetic background (Rouhani
et al., 2014). Adding to this, the differentiation efficiency
of hiPSC-derived neurons can also contribute to variation
seen between lines (Hu et al., 2010). We speculate that
this difference in common genetic variation and differenti-
ation efficiency can result in small variations on a func-
tional level. To correct for line-specific differences and vari-
ability, multiple lines from different individuals should be
used to determine the patient neuronal network
phenotype.
In summary, we here provide a set of guidelines to reduce
the variability in neuronal network recordings on MEAs
(Table 1). We expect that, if cultures are handled according
to these guidelines, our control dataset can be used as a
reference database to determine the performance of
Ngn2-induced control lines. An extensive list of literature
has shown that network parameters can differ between
different sources, neuronal differentiation protocols, or
species (Heikkilä et al., 2009; Hyysalo et al., 2017; Napoli
and Obeid, 2016; Odawara et al., 2016). While we expect
that other neuronal model systems will show network pa-
rameters in a different range than reported here, the guide-
lines that we propose can nevertheless be generalized.
Following these guidelines, MEAs are a valuable tool to
describe the neuronal network phenotypes in hiPSC-
derived neuronal networks.
EXPERIMENTAL PROCEDURES
hiPSC line origin and generation
All hiPSC lines used to generate this dataset were obtained by re-
programmed skin fibroblasts. We used ten hiPSC control lines in
total, of which five are independent control lines (C1, C6-8, and
C10). To illustrate that themodel thatwe use is stable enough to un-
cover patient-specific phenotypes, we included both KS patient
and MELAS patient lines, as well as isogenic patient-control sets.
For KS, we included two isogenic sets consisting of C9 and KS3
and C10 and KS4, which have been described previously in detail
(Frega et al., 2019). In addition, we included two KS patient hiPSC
lines, KS1 and KS2, which were previously characterized and
derived from a 13-year-old female and a 12-year-old female, respec-
tively, diagnosed with KS (Frega et al., 2019). For MELAS, we
included three isogenic sets generated from MELAS individuals
with different levels of m.3242A > G heteroplasmy (0% or
±60%), consisting of C2 andM1, C4 andM2, and C5 andM3, which
have been described previously in detail (Klein Gunnewiek et al.,
2020). All generated hiPSC clones were tested for pluripotency
markers (OCT3/4, SOX2, and NANOG) using immunocytochem-
istry and qPCR. A detailed description of all hiPSC lines included
in this study can be found in the supplemental information.
hiPSCs were cultured on E8 Flex basal medium (Thermo Fisher
Scientific, no. A2858501) supplemented with primocin (0.1 mg/
mL, Invivogen, no. ant-pm-1), puromycin (0.5 mg/mL) (Sigma-Al-
drich, no. P9620) and G418 (50 mg/mL) (Sigma-Aldrich, no.
A1720) at 37C/5% CO2, on either human recombinant laminin
LN521 (Biolamina, no. LN521-02) or Matrigel (Corning, no.
356237)-coated plates. Medium was refreshed every 2 days and
cells were passaged approximately every 3 days using ReLeSR
(STEMCELL Technologies, no. 05873), an enzyme-free passaging
reagent.
Neuronal differentiation and culture
hiPSCs were differentiated into upper layer excitatory cortical neu-
rons by doxycycline-inducible expression of the neuronal tran-
scription factor neurogenin 2 (Ngn2) (Zhang et al., 2013), accord-
ing to a previously published protocol (Frega et al., 2017). To
generate single cells, rtTA/Ngn2-positive hiPSCs were detached by
incubating accutase (Sigma-Aldrich, no. A6964) at 37C/5%CO2
and resuspended in E8 basal medium (Thermo Fisher, no.
A15170-01), supplemented with primocin (0.1 mg/mL), RevitaCell
(Thermo Fisher, no. A2644501) (10 mg/mL), and doxycycline
(Sigma-Aldrich, no. D9891) (4 mg/mL) to induce TetO gene expres-
sion. Cells were plated at a density of 20,000 cells per MEA well
(600 neurons/mm2), which were pre-coated with poly-L-ornithine
hydrobromide (Sigma-Aldrich, no. P3655-10MG) (50mg/mL) and,
depending on experiment, either human recombinant laminin
LN521 (5 mg/mL) or laminin from Engelbreth-Holm-Swarm mu-
rine sarcoma basement membrane ([mouse laminin], Sigma-Al-
drich, no. L2020) (20 mg/mL). At DIV 1, the medium was changed
using filtered DMEM/F12 supplemented with primocin (0.1 mg/
mL), doxycycline (4 mg/mL), 1% N-2 supplement (Thermo Fisher,
no. 17502-048), 1% MEM non-essential amino acid solution
(Sigma-Aldrich, no. M7145), neurotrophin-3 ([NT3] Promokine
no. C-66425) (10 ng/mL), recombinant human brain-derived neu-
rotrophic factor ([BDNF] Promokine, no. C-66212) (10 ng/mL),
and mouse laminin (0.2 mg/mL). At DIV 2, rat embryonic astro-
cytes were added in a 1:1 ratio to support neuronal maturation
and viability (Frega et al., 2017). The medium was changed at
DIV 3 to filtered neurobasal medium (Thermo Fisher, no. 21103-
049) supplemented with primocin (0.1 mg/mL), B-27 (Thermo
Fisher, no. 17504044) (20 mg/mL), GlutaMAX (Thermo Fisher,
no. 35050061) (10 mg/mL), doxycycline (4 mg/mL), NT3 (10 ng/
mL), BDNF (10 ng/mL), and cytosine b-D-arabinofuranoside
(Sigma-Aldrich, no. C1768) (2 mM), to remove proliferating cells
from the culture. From DIV 5 to 9, 50% of the neurobasal medium
supplemented with B-27, GlutaMAX, Pen/Strep, doxycycline,
NT3, and BDNF, was refreshed every 2 days. From DIV 9 to 21 on-
ward the neurobasal mediumwas, in addition, supplemented with
2.5% fetal bovine serum (Sigma-Aldrich, no. F7524) to support
astrocyte viability. All neuronal cultures were kept in incubation
at 37C/5%CO2. Control lines C1, C6, and C7were partly cultured
in the absence of doxycycline from DIV 13 onward. No significant
effect between wells cultured with and without doxycycline were
Stem Cell Reports j Vol. 16 j 2182–2196 j September 14, 2021 2193
found, therefore all data for these respective lines is pooled (data
not shown).
MEA recordings and data analysis
To record spontaneous network activity,multiwellMEAswere used
that consisted of 24 individual wells (Multichannel Systems, MCS
GmbH, Reutlingen, Germany). Each well was embedded with 12
electrodes with a diameter of 30 mm, spaced 300 mm apart. The ac-
tivity of neuronal networks growing on MEAs was recorded for
10min (after a 10min acclimatization period) in a recording cham-
ber that was maintained at 37C/95% O2/5% CO2. The raw signal
was sampled at 10 kHz and filtered with a high-pass second-order
Butterworth filter with a 100 Hz cutoff frequency and a low-pass
fourth-order Butterworth filter with a 3,500 Hz cutoff frequency.
The noise threshold for individual spike detection was set at ±4.5
standard deviations.
Data analysis
Offline data analysis was performed usingMultiwell-Analyzer soft-
ware (Multichannel Systems) that permitted the extraction of
spike-trains, and either a custom-made in-house code developed
in MATLAB (MathWorks, Natick, MA, USA) or a software package
called SPYCODE (Bologna et al., 2010; Frega et al., 2017), which
both allowed the extraction of parameters describing the sponta-
neous network activity. A detailed description of the acquisition
of different MEA parameters can be found in the supplemental
information.
To guarantee sufficient experimental replicates, we included ex-
periments with a minimum of 12 wells per hiPSC line measured
across at least two independent batches. Control neuronal net-
works showing an MFR < 0.1 Hz and BR < 0.4 bursts/min were
excluded from analysis. Wells were excluded from analysis if
they did not have network bursts at DIV 27. Furthermore, wells
that displayed insufficient quality, for example, a low density of
cells or cell clumping, were discarded. All experiments, excluding
experiments where we investigated neuronal network develop-
ment over time, were carried out during a 1-week time interval,
spanning DIV 27 to 35. Since our results, and previous research,
has shown that network burst parameters are stable from DIV 27
onward, data from DIV 27 to 35 were pooled (Frega et al., 2019).
When analyzing multiple developmental time points of one
MEA batch, we determined the network burst detection settings
at the latest DIV and kept these settings throughout the analysis,
working our way backward to the earliest DIV. Wells in which a
reduction of network parameters was observed were also excluded.
Statistical analysis
Data were analyzed using Prism GraphPad 8 (GraphPad Software,
CA, USA). We ensured normal distribution using a Kolmogorov-
Smirnov normality test. To determine statistical significance, p
values < 0.05 were considered to be significant. Statistical analysis
on all control lines in Figures S1F–S1O, S2B, S2C, S3B–S3E, S4F, and
S4G (for KS1 and KS2) were performed using a Kruskal-Wallis
ANOVA with post hoc Dunn’s correction for multiple testing or
one-way ANOVA with Tukey correction or multiple testing de-
pending on the distribution of the data. When comparing means
of two variables at one individual time point we analyzed signifi-
cance between groups bymeans of aMann-WhitneyU test (Figures
3C–3J, 4B–4E, 4I–4L, and S4F) (for KS3 and KS4), and, if applicable,
corrected post hoc for multiple testing using the Bonferroni
method. Statistics on histograms was performed using multiple t
test on bins using the Holm-Sidak method (Figures 3K, 4F, and
4M). Data are presented as mean ± standard error of the mean
(SEM) if not differently specified. Means and p values are reported
in Table S4. To check the variability in the dataset we calculated the
coefficient of variation on each parameter independently for all
control lines (Figures 1J and S3G; Table S2).
Data visualization
PCA was performed on various MEA parameters using the prcomp
function from stats R package (v.3.6.1.) on standardized (Z score
scaled) data. PCA figures were generated using the ggplot function
from the ggplot2 R package (v.3.2.1). A detailed description of the
analysis per PCA plot can be found in the supplemental informa-
tion. A 3D scatterplot wasmade for all control (nwells = 278,Nplates =
47), Kleefstra (nwells = 58, Nplates = 9), and MELAS (nwells = 112,
Nplates = 23) samples together showing PRS, BD, and NBR using
the scatter3d function from scatterplot3d R package (v.0.3-41).
Animals
The rodent astrocytes used in this study were derived from embry-
onic day 18 rat brains, as described previously (Frega et al., 2017;
Mccarthy, 1980). Animal experiments were conducted in confor-
mity with the Animal Care Committee of the Radboud University
Nijmegen Medical Center, the Netherlands, and conform to the
guidelines of the DutchCouncil for Animal Care and the European
Communities Council Directive 2010/63/EU.
Data and code availability
Exports of the raw data (i.e., Peak Trains, which are.mat files con-
taining the timing and amplitude of each detected spike for all
electrodes in one MEA) from all recorded patient and control
MEAs and all codes used in this manuscript have been deposited
on Mendeley data with https://doi.org/10.17632/bvt5swtc5h.1.
SUPPLEMENTAL INFORMATION
Supplemental information can be found online at https://doi.org/
10.1016/j.stemcr.2021.07.001.
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